Drug Trial Radar · NCT04771897
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
May 24, 2021
Primary completion
Oct 4, 2024
Study completion Oct 4, 2024
Sponsor
- Lead sponsor
- Bexion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will enroll patients requiring a biopsy in order to assess BXQ-350 concentrations in the biopsied tumor.
Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
BXQ-350 - Part 1 Dose Escalation: Safety and ToleranceDrug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
BXQ-350 - Part 2 BXQ-350 Tumor and Plasma ConcentrationsDrug
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0Time frame: 12 months
- Part 1 - Maximum Tolerated DoseTime frame: 12 months
- Part 2 - BXQ-350 Concentration in Tumor SamplesTime frame: 12 months
- Part 2 - BXQ-350 Concentration in Plasma SamplesTime frame: 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Nationwide Children's
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.